Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs Live Vital

By GLP-1 ScorecardUpdated

EmbodyFactor scores not reassessed.
Site position #52

Higher score

Live Vital
Site position #233

Lower score

Score comparison

Embody has the higher recorded score — 76.5/100 to 62.7/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody is a low-cost injection option, but the modest prepaid savings deserve a close look beside its payment-finality and renewal rules.

Before you choose

Before comparing the headline prices, the Embody review and the Live Vital review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Embody vs Mondae and Harbor vs Live Vital compare each of them with another graded program, and the list of alternatives to Embody ranks the programs closest to Embody on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueEmbody +15
88
73
Dose & formulationEmbody +31
83
52
Clinical oversightEmbody +15
83
68
Labs & monitoringEmbody +3
54
51
FulfillmentEmbody +20
93
73
Contract termsLive Vital +26
25
51
Embody · top barLive Vital · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricEmbodyLive Vital
WeighScore76.5/10062.7/100
GradeCC
Site position#52#233
Semaglutide$79/mo (monthly plan; twelve-month bundle listed at $49/mo, upfront charge unpublished)From $93/mo (annual plan only; enrollment marked coming soon, compounded)
Tirzepatide$129/mo (monthly plan; twelve-month bundle listed at $99/mo, upfront charge unpublished)From $179/mo (annual plan only; monthly price not published, compounded)
CoverageState eligibility not fully published; confirm your locationAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Embody

Site position #52 · C

Factor scores not reassessed.

Strengths

  • Monthly plans at $79 semaglutide and $129 tirzepatide in the published terms
  • Separate monthly, three-, six- and twelve-month price tiers published
  • OpenLoop care network and four pharmacy partners publicly named; individual assignment still needs confirmation

What to consider

  • Payments are described as final at purchase except provider-initiated medical disqualification, with used services deducted
  • Cancel at least 72 hours before renewal; unused prepaid months are not routinely refundable
  • Homepage week counts differ from product month labels; confirm supply and charge dates
  • Current catalog supports injections; no active oral-gum offer or universal state footprint confirmed
Live Vital

Site position #233 · C

Strengths

  • Names its medical director
  • Uses a licensed 503A pharmacy and serves all 50 states
  • Phone and text support numbers are published

What to consider

  • The low prices require an annual plan, and no month-to-month price is published
  • The FAQ quotes $95 to $200 a month on 10-week or two-month billing, which does not match the plan prices
  • Semaglutide is not yet open for enrollment
  • Unfinished editorial notes about the pharmacy and payment timing were visible on its own about and refund pages

Featured provider

Live Vital

Live Vital scores 62.7/100 (C). Live Vital is a Utah telehealth company enrolling patients for compounded tirzepatide from $179 a month on an annual plan, with semaglutide listed as coming soon.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard